La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Talphera Résultats passés
Passé contrôle des critères 0/6
Talphera has been growing earnings at an average annual rate of 40.3%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 40.7% per year.
Informations clés
40.3%
Taux de croissance des bénéfices
52.9%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 6.0% |
Taux de croissance des recettes | -40.7% |
Rendement des fonds propres | -83.9% |
Marge nette | -3,443.2% |
Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
AcelRx: The Catalogue Of Catalysts - Including A Big One That Will Do Investors Well
Aug 18AcelRx Pharmaceuticals: Finally, Plan B
Jun 06AcelRx Pharmaceuticals: Making Sense Of The Q4 Numbers
Mar 16AcelRx Pharmaceuticals: The Fog Is Getting Thicker
Jan 14AcelRx: Battered And Bruised But Ready For Recovery In 2022
Jan 05AcelRx Pharmaceuticals: Is Wayne Gretzky Right Or The Puck?
Oct 02AcelRx Pharmaceuticals: How The Licensing Agreements Could Become A Shot In The Arm
Jul 27FDA agrees with AcelRx to update promotional materials for Dsuvia
Jun 17Shareholders May Find It Hard To Justify Increasing AcelRx Pharmaceuticals, Inc.'s (NASDAQ:ACRX) CEO Compensation For Now
Jun 11AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles
May 31Ventilation des recettes et des dépenses
Comment Talphera gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 24 | 0 | -14 | 10 | 0 |
31 Mar 24 | 1 | -14 | 11 | 0 |
31 Dec 23 | 1 | -10 | 12 | 0 |
30 Sep 23 | 0 | -11 | 14 | 0 |
30 Jun 23 | 0 | -14 | 16 | 0 |
31 Mar 23 | 0 | 58 | 17 | 0 |
31 Dec 22 | 0 | 54 | 17 | 0 |
30 Sep 22 | -2 | 69 | 2 | 0 |
30 Jun 22 | -1 | 65 | 7 | 0 |
31 Mar 22 | 2 | -31 | 27 | 0 |
31 Dec 21 | 0 | -17 | 15 | 0 |
30 Sep 21 | 4 | -36 | 33 | 0 |
30 Jun 21 | 3 | -37 | 30 | 0 |
31 Mar 21 | 6 | -33 | 31 | 0 |
31 Dec 20 | 5 | -40 | 36 | 0 |
30 Sep 20 | 5 | -46 | 41 | 0 |
30 Jun 20 | 4 | -50 | 46 | 0 |
31 Mar 20 | 2 | -55 | 48 | 0 |
31 Dec 19 | 2 | -53 | 45 | 0 |
30 Sep 19 | 2 | -51 | 40 | 0 |
30 Jun 19 | 2 | -51 | 34 | 0 |
31 Mar 19 | 2 | -49 | 27 | 0 |
31 Dec 18 | 2 | -47 | 21 | 0 |
30 Sep 18 | 2 | -44 | 17 | 0 |
30 Jun 18 | 3 | -45 | 16 | 0 |
31 Mar 18 | 5 | -48 | 16 | 0 |
31 Dec 17 | 8 | -52 | 17 | 0 |
30 Sep 17 | 14 | -51 | 17 | 0 |
30 Jun 17 | 16 | -50 | 17 | 0 |
31 Mar 17 | 17 | -48 | 16 | 0 |
31 Dec 16 | 17 | -43 | 16 | 0 |
30 Sep 16 | 13 | -44 | 16 | 0 |
30 Jun 16 | 25 | -28 | 14 | 0 |
31 Mar 16 | 22 | -25 | 13 | 0 |
31 Dec 15 | 19 | -24 | 14 | 0 |
30 Sep 15 | 18 | -28 | 15 | 0 |
30 Jun 15 | 7 | -32 | 17 | 0 |
31 Mar 15 | 5 | -34 | 19 | 0 |
31 Dec 14 | 5 | -33 | 18 | 0 |
30 Sep 14 | 33 | -2 | 17 | 0 |
30 Jun 14 | 28 | -13 | 15 | 0 |
31 Mar 14 | 29 | -20 | 12 | 0 |
31 Dec 13 | 30 | -23 | 10 | 0 |
30 Sep 13 | 4 | -52 | 8 | 0 |
Des revenus de qualité: TLPH is currently unprofitable.
Augmentation de la marge bénéficiaire: TLPH is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: TLPH is unprofitable, but has reduced losses over the past 5 years at a rate of 40.3% per year.
Accélération de la croissance: Unable to compare TLPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: TLPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Rendement des fonds propres
ROE élevé: TLPH has a negative Return on Equity (-83.9%), as it is currently unprofitable.